Alvaro Guimaraes

Medical Onc. at Brazilian National Cancer Institute and CROMA Oncologia 🇧🇷 Former Postdoc Research Fellow - Thoracic/H&N Dept. MD Anderson Cancer Center 🇺🇸

[Alvaro Guimaraes @alvaroonco]

On line today at @JTOonline our Brief Report evaluating the chemo/RET combo strategy after progression on a RET TKI in patients with RET+ NSCLC. Looking forward to seeing prospective data evaluating this strategy. @lungoncdoc @StephenVLiu @OncodailyLung
https://t.co/kr3lsREPj1

[Alvaro Guimaraes @alvaroonco]

@Amirali_karimii Huge congrats - really happy for you, my friend! 👏🏽👏🏽

[NEJM @NEJM]

In a phase 1 study of the oral p53 reactivator rezatapopt in heavily pretreated patients with TP53 Y220C–mutated solid tumors, the most common adverse events were nausea and vomiting, and the overall response was 20%. Full PYNNACLE study results: https://t.co/LBqROGlouc

Science behind the Study: Restoring Function to a Variant of p53 in Solid Tumors https://t.co/5Ox6Kuax6Q

[Xiuning Le MD PhD @LeXiuning]

I also want to thank the incredible teams at @MDAndersonNews, @broadinstitute , and @Bayer, we push the boundaries of precision oncology for patients. We delivered high quality work 💪 💪 💪 yet remain fun 😃 and humble ♥️ @NEJM @myESMO #ESMO25

[Alvaro Guimaraes @alvaroonco]

@CamilaBragancaX @MDAndersonNews Well deserved! Best of luck in your new journey, Camila!

[Alvaro Guimaraes @alvaroonco]

🚀Heading to @ASCO 2025 and excited to share our work on RET-fusion NSCLC and a specific RETi AE

📊73 patients treated at MDACC
🔑KTs
💊Both agents can induce chylous effusion
📈12% incidence
✅1st reported case of chylopericardium
❗No drug discontinuation

See you at #ASCO2025

[Jill Feldman @jillfeldman4]

Science has never brought me to tears until today. This poster was presented at #AACR25. The study used a cell line based on paired molecular profiling of biopsies derived from my dear friend @ivybelkins cancer.

Ivy's voice helped shape research, and now her cells are helping to drive progress - a full circle moment. Thank you @alvaroonco, for recognizing and honoring Ivy's memory and contribution to research.
#LCSM #AdvocacyMatters #PowerOfPatientAdvocates

[Eric K. Singhi, MD @lungoncdoc]

🔥 HOT off the press—Our Dr. John Heymach @MDAndersonNews presents on BEAMION-Lung 1.

Oral zongertinib 120 mg QD in previously-treated HER2+ mNSCLC:

✔️ORR 71%
✔️mPFS 12.4 mo
🧠Intracranial ORR 41%
⚠️No ILD, only 1 patient w/ grade 3 diarrhea

#AACR25 @AACR @OncoAlert @NEJM

[Alvaro Guimaraes @alvaroonco]

Such a pleasure and honor to catch up with my mentor John Heymach — Thoracic Chair at MDACC — and Jill Feldman, an extraordinary person and passionate lung cancer advocate. A huge thank you to the EGFR Resisters group for their meaningful support. https://t.co/JzAyhJacpz

[Alvaro Guimaraes @alvaroonco]

Happy to share our publication led by @mvnegrao just came out in @CCR_AACR
It provides new insights into biomarkers and transcriptional signatures in difficult-to-treat KRAS G12C NSCLC! @MDAndersonNews

[Marcelo Negrao @mvnegrao]

Our manuscript is out @CCR_AACR - great team work to improve #lcsm pt outcomes @MDAndersonNews @KRASKickers @LungCancerRx @VJOncology @DavidHongMD @skopetz

Impact of co-mutations and transcriptional signatures in NSCLC patients treated with adagrasib https://t.co/Svkm957kmk

[Alvaro Guimaraes @alvaroonco]

“Thrilled to share this groundbreaking results on STK11/KEAP1-mutant NSCLC. The work highlights the role of CTLA-4 blockade in overcoming PD-1/PD-L1 resistance in this population. Such an honor to contribute to this cutting-edge research.” https://t.co/XqjTQ3XFTn

[Stephen V Liu, MD @StephenVLiu]

Now @NEJM from Dr. Tina Cascone et al - phase 3 CheckMate 77T results: addition of neoadjuvant plus adjuvant nivolumab to neoadjuvant chemo in pts with resectable NSCLC improves pCR (25.3% to 4.7%) and EFS (HR 0.58) with no new safety signals.

https://t.co/e4kwppw25t

[UT MD Anderson @UTMDAnderson]

MD Anderson is again #1 in the nation for cancer care in @USNews’ “Best Hospitals” ranking: https://t.co/DpQfLjSt2G

Thanks to all who make this possible: our faculty, employees, trainees, students, volunteers, donors, advocates, partners, patients and caregivers. #BestHospitals #EndCancer

[Guilherme Harada @HaradaGuilherme]

🚨“Rare” molecular subtypes of lung cancer: why should we care?

📝In this review out @NatRevClinOncol, we highlight that many rare molecular subtypes of lung cancer individually account for a substantial number of patients diagnosed around the world.🧵

https://t.co/8l8h4NhwfJ

[Narjust Florez, MD, FASCO @NarjustFlorezMD]

Remember that once you dreamed of being where you are now …

Those days studying for USMLE Step 1, you used to day dream about today

[Jordi Remon @JordiRemon]

Summary🗓️:We will start 2023 with new strategies with immunotherapy or targeted therapies 👏🏻in advanced lung cancer. However, one size does not fit all 👕👗. 🔮Dynamic treatment approaches based on ctDNA and antibody drug conjugated will be relevant in 2023 @OncoAlert #lungcancer